206 results on '"Yadav PD"'
Search Results
2. Genomic analysis confirmed the importation of first mPox Clade Ib case in Kerala, India from Dubai, UAE.
- Author
-
Shete AM, Chenayil S, Sahay RR, Sindhu CB, Yadav S, Gawande P, Patil DY, Kumar A, Mohandas S, and Yadav PD
- Abstract
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2024
- Full Text
- View/download PDF
3. Comparative immune profiling in survivors of the 2023 Nipah outbreak in Kerala state, India.
- Author
-
Sahay RR, Palav HC, Shete AM, Patil DY, Mohandas S, Radhakrishnan C, Shihabudheen P, Kumar A, Moorkoth AP, Mohite N, Gurav P, Pullor NK, Jain R, Joshi Y, Ramakrishnan LV, Gupta N, Patel V, and Yadav PD
- Subjects
- Humans, India epidemiology, Male, Adult, Female, Survivors, CD8-Positive T-Lymphocytes immunology, Middle Aged, Nipah Virus immunology, Henipavirus Infections immunology, Henipavirus Infections epidemiology, Disease Outbreaks
- Abstract
Immune profiling of Nipah virus (NiV) infection survivors is essential for advancing our understanding of NiV pathogenesis, improving diagnostic and therapeutic strategies, and guiding public health efforts to prevent future outbreaks. There is currently limited data available on the immune response to NiV infection. We aimed to elucidate the specific immune mechanisms involved in protection against NiV infection by analyzing the immune profiles of survivors of the Nipah outbreak in Kerala, India 2023. Immune cell populations were quantified and compared between survivors (up to 4 months post onset day of illness) and healthy controls. Statistical analysis was performed to explore associations between immune profiles and clinical outcomes. Immune signatures common to all three cases were: a heretofore undescribed persistent lymphopenia including the CD4+ Treg compartment with the relative expansion of memory Tregs; trends indicative of global leukopenic modulation were observed in monocytes and granulocytes including an expansion of putatively immunosuppressive low-density granulocytes described recently in the context of severe COVID-19; altered mucosal homing with respect to integrin beta-7 (ITGB7) expressing subsets; increased mobilization of activated T-cells (CD4+ and CD8+) and plasmablasts in the early phase of infection. Comparative analysis based on clinical presentation and outcome yielded lower initial viremia, increased activated T-cell responses, expanded plasmablasts, and restoration of ITGB7 expressing CD8+ T-cells as possible protective signatures. This longitudinal study delineates putative protective signatures associated with milder NiV disease. It emphasizes the need for the development of immunotherapeutic interventions such as monoclonal antibodies to blunt early viremia and ameliorate pathogenesis., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
4. Editorial: Emerging (non) zoonotic viral diseases.
- Author
-
Yadav PD and Patil DY
- Subjects
- Humans, Animals, Zoonoses virology, Zoonoses transmission, Communicable Diseases, Emerging virology, Virus Diseases virology
- Published
- 2024
- Full Text
- View/download PDF
5. Phylo-geo haplotype network-based characterization of SARS-CoV-2 strains circulating in India (2020-2022).
- Author
-
Potdar VA, Laxmivandana R, Walimbe AM, Jadhav SK, Pawar P, Kaledhonkar A, Gupta N, Kaur H, Narayan J, Yadav PD, Abraham P, and Cherian S
- Subjects
- India epidemiology, Humans, Betacoronavirus genetics, Pandemics, Genome, Viral genetics, Haplotypes genetics, SARS-CoV-2 genetics, SARS-CoV-2 isolation & purification, SARS-CoV-2 pathogenicity, COVID-19 genetics, COVID-19 virology, COVID-19 epidemiology, Phylogeny
- Abstract
Background & objectives Genetic analysis of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) strains circulating in India during 2020-2022 was carried out to understand the evolution of potentially expanding and divergent clades. Methods SARS-CoV-2 sequences (n=612) randomly selected from among the sequences of samples collected through a nationwide network of Virus Research Diagnostic Laboratories during 2020 (n=1532) and Indian sequences available in Global Initiative on Sharing All Influenza Data during March 2020-March 2022 (n=53077), were analyzed using the phylo-geo haplotype network approach with reference to the Wuhan prototype sequence. Results On haplotype analysis, 420 haplotypes were revealed from 643 segregating sites among the sequences. Haplotype sharing was noted among the strains from different geographical regions. Nevertheless, the genetic distance among the viral haplotypes from different clades could differentiate the strains into distinct haplo groups regarding variant emergence. Interpretation & conclusions The haplotype analysis revealed that the G and GR clades were co-evolved and an epicentrefor the evolution of the GH, GK and GRA clades. GH was more frequently identified in northern parts of India than in other parts, whereas GK was detected less in north India than in other parts. Thus, the network analysis facilitated a detailed illustration of the pathways of evolution and circulation of SARS-CoV-2 variants.
- Published
- 2024
- Full Text
- View/download PDF
6. Multi-epitope vaccine design using in silico analysis of glycoprotein and nucleocapsid of NIPAH virus.
- Author
-
Kumar A, Misra G, Mohandas S, and Yadav PD
- Subjects
- Humans, Henipavirus Infections prevention & control, Henipavirus Infections immunology, Computer Simulation, Epitopes immunology, Epitopes chemistry, Molecular Dynamics Simulation, Nucleocapsid immunology, Molecular Docking Simulation, Nipah Virus immunology, Viral Vaccines immunology, Glycoproteins immunology, Glycoproteins chemistry
- Abstract
According to the 2018 WHO R&D Blueprint, Nipah virus (NiV) is a priority disease, and the development of a vaccine against NiV is strongly encouraged. According to criteria used to categorize zoonotic diseases, NiV is a stage III disease that can spread to people and cause unpredictable outbreaks. Since 2001, the NiV virus has caused annual outbreaks in Bangladesh, while in India it has caused occasional outbreaks. According to estimates, the mortality rate for infected individuals ranges from 70 to 91%. Using immunoinformatic approaches to anticipate the epitopes of the MHC-I, MHC-II, and B-cells, they were predicted using the NiV glycoprotein and nucleocapsid protein. The selected epitopes were used to develop a multi-epitope vaccine construct connected with linkers and adjuvants in order to improve immune responses to the vaccine construct. The 3D structure of the engineered vaccine was anticipated, optimized, and confirmed using a variety of computer simulation techniques so that its stability could be assessed. According to the immunological simulation tests, it was found that the vaccination elicits a targeted immune response against the NiV. Docking with TLR-3, 7, and 8 revealed that vaccine candidates had high binding affinities and low binding energies. Finally, molecular dynamic analysis confirms the stability of the new vaccine. Codon optimization and in silico cloning showed that the proposed vaccine was expressed to a high degree in Escherichia coli. The study will help in identifying a potential epitope for a vaccine candidate against NiV. The developed multi-epitope vaccine construct has a lot of potential, but they still need to be verified by in vitro & in vivo studies., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Kumar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
7. Crimean-Congo hemorrhagic fever virus prevalence in livestock of Jabalpur, Madhya Pradesh, Central India and its implications for public health.
- Author
-
Manjunathachar HV, Raut CG, Tiwari P, Chouksey V, Barde PV, Yadav PD, Sharma RK, and Das A
- Subjects
- Animals, Cattle, Livestock, Public Health, Prevalence, Seroepidemiologic Studies, Goats, Antibodies, Viral, India epidemiology, Immunoglobulin G, Hemorrhagic Fever Virus, Crimean-Congo, Hemorrhagic Fever, Crimean epidemiology, Hemorrhagic Fever, Crimean veterinary, Goat Diseases epidemiology
- Abstract
The rise of Crimean-Congo Hemorrhagic Fever (CCHF), poses a significant global health challenge, urging immediate action and continuous surveillance. With no available vaccines, monitoring pathogen presence is critical to identify at-risk areas promptly. A study was designed to assess the incidence of CCHF virus in goats and cattle using commercial ELISA IgG kits in tribal-dominated regions. Overall, 16% of the samples (n = 63/393) were positive for CCHF virus-specific IgG antibodies, whereas sero-prevalence detected in cattle 11.6% [95% CI:7-17.7] and in goats 18.9% [95% CI: 13.76-24.01], respectively. Statistically, Animal gender and age didn't significantly affect prevalence (p-value >0.05). Our finding indicates unnoticed CCHF virus circulation. Notably, lack of public awareness about zoonotic diseases in the study region was recorded. To combat this emerging tick-borne disease effectively, it's crucial to screen individuals with hemorrhagic manifestations in healthcare settings and active surveillance of ticks to prevent unwarranted public health outbreaks and design preventive interventions., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the research. Declaration of Generative AI and AI-assisted technologies in the writing process. The authors declare that generative artificial intelligence (AI) and AI-assisted technologies were used to improve readability and language. The author(s) reviewed and edited the content as needed and take full responsibility for the content of the publication., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. Surveillance of Nipah virus in Pteropus medius of Kerala state, India, 2023.
- Author
-
Balasubramanian R, Mohandas S, Thankappan UP, Shete A, Patil D, Sabarinath K, Mathapati B, Sahay R, Patil D, and Yadav PD
- Abstract
Introduction: Since 2018, the Indian state of Kerala has reported four Nipah virus (NiV) disease outbreaks, raising concerns about NiV spillover from bats to the human population. Considering this, a cross-sectional study was undertaken in the Pteropus medius bat population around the Nipah virus-affected regions of Kozhikode, Kerala, India, during February, July, and September 2023., Methods: Throat swabs, rectal swabs, and organ samples were collected from bats to test for NiV using the real-time reverse transcriptase polymerase chain reaction (RT-PCR), while serum samples were screened for anti-Nipah IgG antibodies through ELISA., Results: An overall seroprevalence of 20.9% was observed in 272 P. medius bats tested. The throat and rectal swab samples of 321 bats were negative for NiV RNA. However, 4 of 44 P. medius bats tested positive for NiV in their liver/spleen samples. The partial N gene retrieved showed more than 99% similarity with the earlier reported NiV genome from Kerala state, India., Discussion: The findings of the study caution that there is a spillover risk in the region and necessary precautions should be taken., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2024 Balasubramanian, Mohandas, Thankappan, Shete, Patil, Sabarinath, Mathapati, Sahay, Patil and Yadav.)
- Published
- 2024
- Full Text
- View/download PDF
9. Cellular Immune Responses Against γ-Inactivated Antigen in the Recovered Cases of Kyasanur Forest Disease.
- Author
-
Kaushal H, Kartaskar RS, Chiplunkar T, Yadav PD, Awate P, Potdar VA, Khalipe MM, Saraf C, Shete AM, Sahay RR, Das S, Chandrakant SA, and Alagarasu K
- Subjects
- Humans, CD8-Positive T-Lymphocytes, Leukocytes, Mononuclear, Immunity, Cellular, Kyasanur Forest Disease, Encephalitis Viruses, Tick-Borne
- Abstract
Kyasanur Forest Disease Virus (KFDV) is a tick-borne flavivirus that causes life-threatening hemorrhagic fever in humans with case fatality rates of 3-5%. Relatively little is known about the mechanism of its pathogenesis or host immune responses to KFDV infection. Here, we investigated KFDV-specific cellular immune responses in the recovered cases of Kyasanur Forest Disease (KFD). Peripheral blood mononuclear cells of the recovered KFD cases and healthy controls were exposed to γ-inactivated KFDV antigen ex vivo . The proliferation index was determined using an enzyme-linked immunosorbent assay-based lymphoproliferative assay. The frequencies of CD4
+ and CD8+ T cells expressing intracellular interferon (IFN)-γ in response to stimulation with γ-inactivated KFDV antigen were determined using flow cytometry. A significant increase in lymphoproliferation and a high frequency of CD4+ and CD8+ T cells secreting IFN-γ against γ-inactivated KFDV antigen were found in the recovered KFD group compared to the healthy control group. In conclusion, the study indicated the generation of cellular immune responses in individuals who recovered from KFD and can be used as indicators of cellular immunity in KFD vaccine studies.- Published
- 2024
- Full Text
- View/download PDF
10. Clinico-epidemiological presentations and management of Nipah virus infection during the outbreak in Kozhikode district, Kerala state, India 2023.
- Author
-
As AK, Sahay RR, Radhakrishnan C, P S, Kandath S, Patil DY, Shete AM, M S, Ramakrishnan G, Moorkoth AP, Gupta N, Yadav PD, Godbole S, Ramakrishnan LV, Vadekkandiyil S, Ekkalayil D, V N, Balakrishnan A, Pullor NK, Asokan N, Joseph RK, Nair PR, Purayil SM, Mathew T, Kizhakkekandiyil R, Poovullathil JK, Ps KS, Pt U, George K, Rahim A, Kumar S, S S, Mohandas S, Rajan LS, Ramachandran SP, Thampi SP, Ashadevi, Anish TS, Chandran P, Mohan A, Vadakkayil B, Koroth SC, Hafeez N, Sasi RR, and Abraham M
- Subjects
- Animals, Humans, Disease Outbreaks, India epidemiology, RNA, Viral genetics, Henipavirus Infections diagnosis, Henipavirus Infections epidemiology, Nipah Virus genetics, Chiroptera
- Abstract
India experienced its sixth Nipah virus (NiV) outbreak in September 2023 in the Kozhikode district of Kerala state. The NiV is primarily transmitted by spillover events from infected bats followed by human-to-human transmission. The clinical specimens were screened using real-time RT-PCR, and positive specimens were further characterized using next-generation sequencing. We describe here an in-depth clinical presentation and management of NiV-confirmed cases and outbreak containment activities. The current outbreak reported a total of six cases with two deaths, with a case fatality ratio of 33.33%. The cases had a mixed presentation of acute respiratory distress syndrome and encephalitis syndrome. Fever was a persistent presentation in all the cases. The Nipah viral RNA was detected in clinical specimens until the post-onset day of illness (POD) 14, with viral load in the range of 1.7-3.3 × 10
4 viral RNA copies/mL. The genomic analysis showed that the sequences from the current outbreak clustered into the Indian clade similar to the 2018 and 2019 outbreaks. This study highlights the vigilance of the health system to detect and effectively manage the clustering of cases with clinical presentations similar to NiV, which led to early detection and containment activities., (© 2024 Wiley Periodicals LLC.)- Published
- 2024
- Full Text
- View/download PDF
11. Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152.
- Author
-
Yadav PD, Sardana V, Deshpande GR, Shinde PV, Thangaraj JWV, George LS, Sapkal GN, Patil DY, Sahay RR, Shete AM, Joshi M, Murhekar M, Godbole S, Gupta N, Prakash S, Rathore M, Ujjainiya R, Singh AP, Mishra A, Dash D, Chaudhary K, and Sengupta S
- Subjects
- Humans, SARS-CoV-2, Antibodies, Neutralizing, Vaccination, Antibodies, Viral, ChAdOx1 nCoV-19, COVID-19 prevention & control, COVID-19 Vaccines, Vaccines, Inactivated
- Abstract
Background Objectives: The Omicron sub-lineages are known to have higher infectivity, immune escape and lower virulence. During December 2022 - January 2023 and March - April 2023, India witnessed increased SARS-CoV-2 infections, mostly due to newer Omicron sub-lineages. With this unprecedented rise in cases, we assessed the neutralization potential of individuals vaccinated with ChAdOx1 nCoV (Covishield) and BBV152 (Covaxin) against emerging Omicron sub-lineages., Methods: Neutralizing antibody responses were measured in the sera collected from individuals six months post-two doses (n=88) of Covishield (n=44) or Covaxin (n=44) and post-three doses (n=102) of Covishield (n=46) or Covaxin (n=56) booster dose against prototype B.1 strain, lineages of Omicron; XBB.1, BQ.1, BA.5.2 and BF.7., Results: The sera of individuals collected six months after the two-dose and the three-dose demonstrated neutralizing activity against all variants. The neutralizing antibody (NAbs) level was highest against the prototype B.1 strain, followed by BA5.2 (5-6 fold lower), BF.7 (11-12 fold lower), BQ.1 (12 fold lower) and XBB.1 (18-22 fold lower)., Interpretation Conclusions: Persistence of NAb responses was comparable in individuals with two- and three-dose groups post six months of vaccination. Among the Omicron sub-variants, XBB.1 showed marked neutralization escape, thus pointing towards an eventual immune escape, which may cause more infections. Further, the correlation of study data with complete clinical profile of the participants along with observations for cell-mediated immunity may provide a clear picture for the sustained protection due to three-dose vaccination as well as hybrid immunity against the newer variants., (Copyright © 2024 Copyright: © 2024 Indian Journal of Medical Research.)
- Published
- 2024
- Full Text
- View/download PDF
12. Clinical, epidemiological, and molecular investigation of Kyasanur forest disease from Karnataka state, India during 2018-2019.
- Author
-
Munivenkatappa A, Yadav PD, Sahay RR, Sk K, Shete AM, Patil DY, Mohandas S, Jain R, Patil S, Sinha DP, and Jayaswamy MM
- Subjects
- Animals, Humans, India epidemiology, Immunoglobulin M, Haplorhini, Kyasanur Forest Disease epidemiology, Kyasanur Forest Disease diagnosis, Chikungunya Fever epidemiology, Dengue epidemiology
- Abstract
Background: In this study, we carried out an investigation of Kyasanur Forest Disease (KFD) suspected human cases reported in Karnataka state, India from December 2018 to June 2019., Methods: The clinical samples of KFD suspected cases ( n = 1955) from 14 districts of Karnataka were tested for KFD using real-time RT-PCR and IgM ELISA. Further, the KFD-negative samples were tested for IgM antibodies against dengue and chikungunya viruses. Monkey samples ( n = 276) and tick pools ( n = 11582) were also screened using real-time RT-PCR. KFD-positive samples were further analysed using next-generation sequencing along with clinico-epidemiological analysis., Results: Of all, 173 (8.8%) cases tested positive for KFD either by real-time RT-PCR ( n = 124), IgM ELISA ( n = 53) or both tests ( n = 4) from seven districts. Among KFD-negative cases, IgM antibody positivity was observed for dengue (2.6%), chikungunya (5.8%), dengue and chikungunya coinfection (3.7%). KFD cases peaked in January 2019 with fever, conjunctivitis, and myalgia as the predominant symptoms and a mortality of 4.6%. Among confirmed cases, 41% received a single dose and 20% received two doses of the KFD vaccine. Of the seven districts with KFDV positivity, Shivamogga and Hassan districts reported KFD viral RNA positivity in humans, monkeys, and ticks. Sequencing analysis of 2019 cases demonstrated a difference of less than 1.5% amino acid compared to prototype KFDV., Conclusion: Although the KFD has been endemic in many districts of Karnataka state, our study confirms the presence of KFDV for the first time in two new districts, i.e. Hassan and Mysore. A comparative analysis of KFDV infection among the KFD-vaccinated and non-vaccinated populations demonstrated an insignificant difference.
- Published
- 2024
- Full Text
- View/download PDF
13. Enterovirus Coxsackie A16 Detected in Hand, Foot, and Mouth Disease Outbreak Among Children in Western Uttar Pradesh, India, May to June 2022.
- Author
-
Diwate S, Yadav PD, Yadav J, and Yadav AK
- Subjects
- Child, Humans, Infant, Disease Outbreaks, India epidemiology, Enterovirus, Hand, Foot and Mouth Disease epidemiology
- Abstract
Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
14. Identification of the first Zika virus disease case following the detection in Aedes aegypti from Karnataka state, India.
- Author
-
Munivenkatappa A, Pattassery SA, Shettar AK, and Yadav PD
- Subjects
- Animals, Female, Humans, India, Aedes virology, Mosquito Vectors virology, Zika Virus isolation & purification, Zika Virus genetics, Zika Virus Infection diagnosis, Zika Virus Infection virology
- Published
- 2024
- Full Text
- View/download PDF
15. A rare case of Chandipura virus infection with haemorrhagic complications from Gujarat, India.
- Author
-
Punasanvala P, Sahay RR, Chandegara H, Patil DY, Shete AM, Balachandran C, Patel V, Bondre V, Rustam R, Patel K, Majumdar T, Shah K, Patil S, Sakhare K, Solanki J, Gawande P, Kumari V, and Yadav PD
- Subjects
- Humans, RNA, Viral, Vesiculovirus, India epidemiology, Rhabdoviridae Infections
- Published
- 2023
- Full Text
- View/download PDF
16. A fatal case of Crimean-Congo hemorrhagic fever from Kutch, Gujarat, India 2023.
- Author
-
Sahay RR, Patil DY, Shete AM, Nayak S, Parikh TM, Waghmare VT, Patel A, Shah A, Upadhyay K, Solanki J, Kanani A, and Yadav PD
- Subjects
- Humans, India epidemiology, Hemorrhagic Fever Virus, Crimean-Congo, Hemorrhagic Fever, Crimean diagnosis, Hemorrhagic Fever, Crimean epidemiology
- Published
- 2023
- Full Text
- View/download PDF
17. Broadly Reactive SARS-CoV-2-Specific T-Cell Response and Participation of Memory B and T Cells in Patients with Omicron COVID-19 Infection.
- Author
-
Yadav PD, Sahay RR, Salwe S, Trimbake D, Babar P, Sapkal GN, Deshpande GR, Bhise K, Shete AM, Abraham P, and Tripathy AS
- Subjects
- Humans, CD8-Positive T-Lymphocytes, Antibodies, Viral, Enzyme-Linked Immunospot Assay, SARS-CoV-2, COVID-19
- Abstract
January 2022 onward, India witnessed a sudden increase in Omicron COVID-19 infections, having a mild course that prompted us to identify the key host factors/immune molecules modulating disease course/outcomes. The current study evaluated the percentages of lymphocyte subsets by flowcytometry, SARS-CoV-2 specific T-cell immune response by ELISPOT, estimation of plasma cytokine/chemokine levels on a Bio-plex Multiplex Immunoassay System and anti-SARS-CoV-2 IgG levels by enzyme-linked immunosorbent assay in 19 mild Omicron infected patients, 45 mild SARS-CoV-2 (2020) patients and 36 uninfected controls from India. Natural killer cells, B and memory B cells were high in vaccinated and total Omicron-infected patients groups compared to the mild SARS-CoV-2 (2020) patient group, while CD8
+ T cells were high in total Omicron-infected patients group compared to the uninfected control group ( p < 0.05 each). Omicron-infected patients had T-cell response against SARS-CoV-2 whole virus, S1 proteins (wild type and delta variant) in 10 out of 17 (59%), 10 out of 17 (59%), and 8 out of 17 (47%), respectively. The current study of Omicron-infected patients elucidates broadly reactive antibody, T-cell response, and participation of memory B and T cells induced by vaccination/natural infection. The limited effect of Omicron's mutations on T-cell response is suggestive of protection from severity. Pro-inflammatory IL-6, IFN- γ , chemokines CCL-2, CCL-3, CCL-4, CCL-5, and IL-8 as potential biomarkers of Omicron infection may have future diagnostic importance. The cellular immune response data in Omicron-infected patients with parental Omicron lineage could serve as a starting point to define the readouts of protective immunity against circulating Omicron subvariants., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2023 Pragya D. Yadav et al.)- Published
- 2023
- Full Text
- View/download PDF
18. Whole-genome sequencing and phylogenetic analysis of coxsackievirus-A16 strains causing hand, foot and mouth disease (HFMD) in India.
- Author
-
Tikute S, Sonawane S, Shete A, Kumar A, Yadav S, Yadav PD, and Lavania M
- Subjects
- Humans, Child, Phylogeny, India epidemiology, Nucleotides, Hand, Foot and Mouth Disease epidemiology, Enterovirus genetics
- Abstract
Hand, foot and mouth disease (HFMD) is a common childhood infectious disease, caused by enteroviruses (EVs), which can present with typical or atypical lesions. The illness is self-limiting, but it can also have serious complications. Since 1997, HFMD infections have become endemic and have increased to epidemic proportions across the Asia Pacific region, including India. Coxsackievirus-A16 (CV-A16) outbreaks occurred in India from 2005 onwards, although the clinical symptoms were noticeably different during this period. Understanding the population dynamics of enteroviruses that cause HFMD is crucial in the post-polio era because one of the circulating strain may replace another as the dominant strain. The aim of this study is to describe the genetic features of the CV-A16 strains isolated from hand, foot and mouth disease (HFMD) patients in India. Reverse transcription PCR (RT-PCR) and cell-culture-based isolation of CV-A16 was done from the 55 clinical samples. The entire genome of the CV-A16 isolate was performed from the seven isolates. After the sequences were analysed, a phylogenetic tree was created using bioinformatics tools. The total genomic length obtained was 7411 base pairs (bp). Nucleotide similarity across various regions, including 5'UTR, P1, P2 and 3'UTR, ranged from 87.0-97.9 %, 77.0-95.4 %, 80.3-96.9 %, and 77.9-96.2 %, respectively. Correspondingly, similarities in the VP1 region's nucleotide and amino acid sequences were 91.4-96.4 % and 99.3-99.7 %, respectively. Phylogenetic analysis highlighted that CV-A16 strains identified in Pune, Maharashtra, were grouped within the same cluster. The analysed CV-A16 isolates in this study aligned with subgenotype B1c. These findings have far-reaching implications for the surveillance, prevention and management of HFMD and CV-A16. Monitoring the dynamics of CV-A16 strains, informed by the genetic characteristics identified here, will significantly impact strategies aimed at tackling HFMD and its associated public health challenges.
- Published
- 2023
- Full Text
- View/download PDF
19. Assessment of antibody kinetics in mpox cases with indigenously developed IgM and IgG ELISA.
- Author
-
Shete AM, Patil DY, Jain R, Sahay RR, Chenayil S, Mohandas S, and Yadav PD
- Subjects
- Humans, Kinetics, Enzyme-Linked Immunosorbent Assay, Immunoglobulin G, Immunoglobulin M, Mpox (monkeypox)
- Published
- 2023
- Full Text
- View/download PDF
20. Corrigendum: Editorial: Emerging SARS-CoV-2 variants: genomic variations, transmission, pathogenesis, clinical impact and interventions.
- Author
-
Yadav PD, Kumar S, Bergeron É, and Flora MS
- Abstract
[This corrects the article DOI: 10.3389/fmed.2023.1178696.]., (Copyright © 2023 Yadav, Kumar, Bergeron and Flora.)
- Published
- 2023
- Full Text
- View/download PDF
21. Discovery of Hybrid Thiouracil-Coumarin Conjugates as Potential Novel Anti-SARS-CoV-2 Agents Targeting the Virus's Polymerase "RdRp" as a Confirmed Interacting Biomolecule.
- Author
-
Vishwanath D, Shete-Aich A, Honnegowda MB, Anand MP, Chidambaram SB, Sapkal G, Basappa B, and Yadav PD
- Abstract
The coronavirus (COVID-19) pandemic, along with its various strains, has emerged as a global health crisis that has severely affected humankind and posed a great challenge to the public health system of affected countries. The replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mainly depends on RNA-dependent RNA polymerase (RdRp), a key enzyme that is involved in RNA synthesis. In this regard, we designed, synthesized, and characterized hybrid thiouracil and coumarin conjugates (HTCAs) by ether linkage, which were found to have anti-SARS-CoV-2 properties. Our in vitro real-time quantitative reverse transcription PCR (RT-qPCR) results confirmed that compounds such as 5d , 5e , 5f , and 5i inhibited the replication of SARS-CoV-2 with EC
50 values of 14.3 ± 0.14, 6.59 ± 0.28, 86.3 ± 1.45, and 124 ± 2.38 μM, respectively. Also, compound 5d displayed significant antiviral activity against human coronavirus 229E (HCoV-229E). In addition, some of the HTCAs reduced the replication of SARS-CoV-2 variants such as D614G and B.617.2. In parallel, HTCAs in uninfected Vero CCL-81 cells indicated that no cytotoxicity was noticed. Furthermore, we compared the in silico interaction of lead compounds 5d and 5e toward the cocrystal structure of Suramin and RdRp polymerase with Remdesvir triphosphate, which showed that compounds 5d , 5e , and Remdesvir triphosphate (RTP) share a common catalytical site of RdRp but not Suramin. Additionally, the in silico ADMET properties predicted for the lead HTCAs and RTP showed that the maximum therapeutic doses recommended for compounds 5d and 5e were comparable to those of RTP. Concurrently, the pharmacokinetics of 5d was characterized in male Wistar Albino rats by administering a single oral gavage at a dose of 10 mg/kg, which gave a Cmax value of 0.22 μg/mL and a terminal elimination half-life period of 73.30 h. In conclusion, we established a new chemical entity that acts as a SARS-CoV-2 viral inhibitor with minimal or no toxicity to host cells in the rodent model, encouraging us to proceed with preclinical studies., Competing Interests: The authors declare no competing financial interest., (© 2023 The Authors. Published by American Chemical Society.)- Published
- 2023
- Full Text
- View/download PDF
22. The 2022 outbreak and the pathobiology of the coxsackie virus [hand foot and mouth disease] in India.
- Author
-
Chavan NA, Lavania M, Shinde P, Sahay R, Joshi M, Yadav PD, Tikute S, Waghchaure R, Ashok M, Gupta A, Mittal M, Khan V, Fomda BA, Ahmad M, Tiwari VP, Pote P, Dhongade AR, Mohanty A, Mohan K, Kumar M, and Bhardwaj A
- Subjects
- Child, Humans, Pandemics, Disease Outbreaks, India epidemiology, China epidemiology, Hand, Foot and Mouth Disease epidemiology, COVID-19 epidemiology, Enterovirus genetics, Enterovirus Infections epidemiology
- Abstract
Outbreaks of HFMD in children aged <5 years have been reported worldwide and the major causative agents are Coxsackievirus (CV) A16, enterovirus (EV)-A71 and recently CVA6. In India, HFMD is a disease that is not commonly reported. The purpose of the study was to identify the enterovirus type(s) associated with large outbreak of Hand, foot, and mouth disease during COVID-19 pandemic in 2022. Four hundred and twenty five clinical samples from 196-suspected cases were collected from different parts of the country. This finding indicated the emergence of CVA6 in HFMD along with CVA16, soon after the gradual easing of non-pharmaceutical interventions during-pandemic COVID-19 and the relevance of continued surveillance of circulating enterovirus types in the post-COVID pandemic era., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
23. Persistence of infectious mpox virus on the surfaces of isolation ward in a hospital setting, India.
- Author
-
Sahay RR, Relhan V, Shete AM, Patil DY, Kumar LP, Kaur A, Majumdar T, Agarwal D, Gawande P, Lalmuanpuii G, Yemul J, Bahadur A, Vedpathak P, Guglani A, Gowda P, Mali D, Dighe H, Sarkale P, Kumar A, Jain R, Sahoo B, Kumar S, and Yadav PD
- Subjects
- Humans, India, Monkeypox virus, Hospitals
- Published
- 2023
- Full Text
- View/download PDF
24. Atypical clinical presentation of Zika virus from India.
- Author
-
Shukla S, Yadav PD, Patil S, Jain A, and Aggarawal V
- Subjects
- Humans, India, Zika Virus genetics, Zika Virus Infection diagnosis
- Abstract
Competing Interests: None
- Published
- 2023
- Full Text
- View/download PDF
25. Editorial: Emerging SARS-CoV-2 variants: genomic variations, transmission, pathogenesis, clinical impact, and interventions, volume II.
- Author
-
Yadav PD, Patil DY, Kumar S, Bergeron E, and Rodriguez SE
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
26. Comparative pathogenicity of BA.2.12, BA.5.2 and XBB.1 with the Delta variant in Syrian hamsters.
- Author
-
Mohandas S, Shete A, Kumar A, Wakchaure K, Rai V, Mote C, Dighe H, Sarkale P, Gawande P, Yemul J, Suryawanshi A, Joshi Y, and Yadav PD
- Abstract
Omicron variant is evolving into numerous sub variants with time and the information on the characteristics of these newly evolving variants are scant. Here we performed a pathogenicity evaluation of Omicron sub variants BA.2.12, BA.5.2 and XBB.1 against the Delta variant in 6-8-week-old Syrian hamster model. Body weight change, viral load in respiratory organs by real time RT-PCR/titration, cytokine mRNA quantification and histopathological evaluation of the lungs were performed. The intranasal infection of the BA.2.12, BA.5.2 and XBB.1 variants in hamster model resulted in body weight loss/reduced weight gain, inflammatory cytokine response and interstitial pneumonia with lesser severity compared to the Delta variant infection. Among the variants studied, BA.2.12 and XBB.1 showed lesser viral shedding through the upper respiratory tract, whereas the BA.5.2 showed comparable viral RNA shedding as that of the Delta variant. The study shows that the Omicron BA.2 sub variants may show difference in disease severity and transmissibility amongst each other whereas the overall disease severity of the Omicron sub variants studied were less compared to the Delta variant. The evolving Omicron sub variants and recombinants should be monitored for their properties., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Mohandas, Shete, Kumar, Wakchaure, Rai, Mote, Dighe, Sarkale, Gawande, Yemul, Suryawanshi, Joshi and Yadav.)
- Published
- 2023
- Full Text
- View/download PDF
27. Host immune responses in aged rhesus macaques against BBV152, an inactivated SARS-CoV-2 vaccine, and cross-neutralization with beta and delta variants.
- Author
-
Patil DR, Shete AM, Yadav PD, Sapkal GN, Deshpande GR, Kaushal H, Mohandas S, Fulari S, Jain R, Kumar A, and Abraham P
- Subjects
- Animals, Humans, Aged, Macaca mulatta, SARS-CoV-2, Antibodies, Neutralizing, COVID-19 Vaccines, COVID-19 prevention & control
- Abstract
The magnitude and duration of immune response to COVID-19 vaccination in older adults are known to be adversely affected due to immunosenescence and inflammaging. The threat of emerging variants warrants studies on immune response in older adults to primary vaccination and booster doses so as to understand the effectiveness of vaccines in countering the threat of emerging variants. Non-human primates (NHPs) are ideal translational models, as the immunological responses in NHPs are similar to those in humans, so it enables us to understand host immune responses to the vaccine. We initially studied humoral immune responses in aged rhesus macaques employing a three-dose regimen of BBV152, an inactivated SARS-CoV-2 vaccine. Initially, the study investigated whether the third dose enhances the neutralizing antibody (Nab) titer against the homologous virus strain (B.1) and variants of concern (Beta and Delta variants) in aged rhesus macaques immunized with BBV152, adjuvanted with Algel/Algel-IMDG (imidazoquinoline). Later, we also attempted to understand cellular immunity in terms of lymphoproliferation against γ-inactivated SARS-CoV-2 B.1 and delta in naïve and vaccinated rhesus macaques after a year of the third dose. Following the three-dose regimen with 6 µg of BBV152 with Algel-IMDG, animals had increased Nab responses across all SARS-CoV-2 variants studied, which suggested the importance of booster dose for the enhanced immune response against SARS-CoV-2-circulating variants. The study also revealed the pronounced cellular immunity against B.1 and delta variants of SARS-CoV-2 in the aged rhesus macaques even after a year of vaccination., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Patil, Shete, Yadav, Sapkal, Deshpande, Kaushal, Mohandas, Fulari, Jain, Kumar and Abraham.)
- Published
- 2023
- Full Text
- View/download PDF
28. An imported case of fatal encephalitis associated with mpox virus infection, India, July 2022.
- Author
-
Yadav PD, Vasu M, Abubaker F, Sahay RR, Reghukumar A, Krishnan AB, Prabha K, Papu AK, Gopalakrishnan LG, Mundangalam N, Siddiq A, Patil DY, Shete AM, Abraham P, Prasad AR, Thavakara Koolothuvalappil A, and Karunakaran K
- Subjects
- Humans, India, Encephalitis diagnosis, Encephalitis, Japanese diagnosis, Mpox (monkeypox), Virus Diseases
- Published
- 2023
- Full Text
- View/download PDF
29. A case of human buffalopox in Malappuram, India: The role of mpox surveillance in 2022.
- Author
-
Patil DY, George S, Sahay RR, Chenayil S, Shete AM, Bhaskaramenon SC, Anish TS, Jain R, Nazeer FA, John R, Joshi Y, Sivaprasad R, Waghmare P, Ray S, Balakrishnan S, Kumari V, Sathe S, and Yadav PD
- Subjects
- Humans, Vaccinia virus, India epidemiology, Mpox (monkeypox), Vaccinia
- Published
- 2023
- Full Text
- View/download PDF
30. Needle-free injection system delivery of ZyCoV-D DNA vaccine demonstrated improved immunogenicity and protective efficacy in rhesus macaques against SARS-CoV-2.
- Author
-
Yadav PD, Kumar S, Agarwal K, Jain M, Patil DR, Maithal K, Mathapati B, Giri S, Mohandas S, Shete A, Sapkal G, Patil DY, Dey A, Chandra H, Deshpande G, Gupta N, Abraham P, Kaushal H, Sahay RR, Tripathy A, Nyayanit D, Jain R, Kumar A, Sarkale P, Baradkar S, Rajanathan C, Raju HP, Patel S, Shah N, Dwivedi P, and Singh D
- Subjects
- Animals, SARS-CoV-2, Macaca mulatta, Antibodies, Neutralizing, Antibodies, Viral, Immunogenicity, Vaccine, COVID-19, Vaccines, DNA, Viral Vaccines
- Abstract
The apprehension of needles related to injection site pain, risk of transmitting bloodborne pathogens, and effective mass immunization have led to the development of a needle-free injection system (NFIS). Here, we evaluated the efficacy of the NFIS and needle injection system (NIS) for the delivery and immunogenicity of DNA vaccine candidate ZyCoV-D in rhesus macaques against SARS-CoV-2 infection. Briefly, 20 rhesus macaques were divided into 5 groups (4 animals each), that is, I (1 mg dose by NIS), II (2 mg dose by NIS), III (1 mg dose by NFIS), IV (2 mg dose by NFIS) and V (phosphate-buffer saline [PBS]). The macaques were immunized with the vaccine candidates/PBS intradermally on Days 0, 28, and 56. Subsequently, the animals were challenged with live SARS-CoV-2 after 15 weeks of the first immunization. Blood, nasal swab, throat swab, and bronchoalveolar lavage fluid specimens were collected on 0, 1, 3, 5, and 7 days post infection from each animal to determine immune response and viral clearance. Among all the five groups, 2 mg dose by NFIS elicited significant titers of IgG and neutralizing antibody after immunization with enhancement in their titers postvirus challenge. Besides this, it also induced increased lymphocyte proliferation and cytokine response. The minimal viral load post-SARS-CoV-2 challenge and significant immune response in the immunized animals demonstrated the efficiency of NFIS in delivering 2 mg ZyCoV-D vaccine candidate., (© 2023 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
31. First detection of Varicella Zoster Virus clade 9 cases in India during mpox surveillance.
- Author
-
Kumar A, Rajan LS, Sabarinath Ps K, Shete AM, Sahay RR, Patil DY, Ingole N, K K, Padinakarai AC, Gb S, Shastri J, Padukone S, Joshi Y, Patil S, Majumdar T, Verma A, Yemul J, Shende N, Kumari V, Vedpathak P, Sathe S, Gawande P, and Yadav PD
- Subjects
- Adult, Child, Humans, Phylogeny, Genomics, India epidemiology, Herpesvirus 3, Human genetics, Mpox (monkeypox)
- Abstract
Background: The multi-country mpox outbreak across the globe has led to the systematic surveillance of mpox cases in India. During the surveillance of mpox, we encountered cases of Varicella Zoster Virus (VZV) in suspected mpox cases amongst children & adults. This study focused on the genomic characterization of VZV in India., Methods: A total of 331 mpox suspected cases were tested for VZV through real-time PCR, and the positive samples were subjected to next-generation sequencing to retrieve the whole genome of VZV using CLC genomics software. Phylogenetic analysis has been done in MEGA 11.0 software to identify circulating clades., Result: Of the 331 suspected cases, 28 cases with vesicular rashes were found to be positive for VZV. The maximum genome could be retrieved from the clinical specimens of 16 cases with coverage greater than 98% when mapped with reference strain Dumas (NC 001348). The phylogenetic analyses of these sequences determined the circulation of clades 1, 5, and 9 in India. Further, the sequence analysis demonstrated non-synonymous single nucleotide polymorphism (SNPs) among specific ORF of VZV including ORF 14, ORF 22, ORF 36, ORF 37 and ORF 51. Although clade 1 and 5 has been reported earlier, the circulation of clade 9 of VZV has been determined for the first time in India., Conclusion: Although the circulation of different clades of VZV was reported from India, the presence of clade 9 was detected for the first time during the mpox surveillance.
- Published
- 2023
- Full Text
- View/download PDF
32. Molecular characterization & recombination analysis of complete enterovirus-88 isolated from acute flaccid paralysis cases in India.
- Author
-
Munivenkatappa A, Nyayanit DA, Mohandas S, Luwang A, Shete A, Hanumaiah H, Mourya DT, and Yadav PD
- Subjects
- Humans, alpha-Fetoproteins genetics, Paralysis, Phylogeny, India, Recombination, Genetic, Enterovirus genetics, Enterovirus Infections complications, Myelitis complications
- Abstract
Background & Objectives: Focus on non-polio enteroviruses (NPEVs) causing acute flaccid paralysis (AFP) due to myelitis has increased with the containment of the poliovirus. Enterovirus-B88 (EV-B88) has been associated with the AFP cases in Bangladesh, Ghana, South Africa, Thailand and India. In India, EV-B88 infection was linked to AFP a decade ago; however, to date, no complete genome has been made available. In this study, the complete genome sequence of EV-B88 was identified and reported from two different States (Bihar and Uttar Pradesh) in India using the next-generation sequencing technique., Methods: Virus isolation was performed on the three AFP suspected cases as per the WHO-recommended protocol. Samples showing cytopathic effects in the human Rhabdocarcinoma were labelled as NPEVs. Next-generation sequencing was performed on these NPEVs to identify the aetiological agent. The contiguous sequences (contigs) generated were identified, and reference-based mapping was performed., Results: EV-B88 sequences retrieved in our study were found to be 83 per cent similar to the EV-B88 isolate from Bangladesh in 2001 (strain: BAN01-10398; Accession number: AY843306.1). Recombination analyses of these samples demonstrate recombination events with sequences from echovirus-18 and echovirus-30., Interpretation & Conclusions: Recombination events in the EV-B serotypes are known, and this work reconfirms the same for EV-B88 isolates also. This study is a step in increasing the awareness about EV-B88 in India and emphasizes future studies to be conducted in the identification of other types of EV present in India.
- Published
- 2023
- Full Text
- View/download PDF
33. Clinical presentation, viral kinetics, and management of human monkeypox cases from New Delhi, India 2022.
- Author
-
Relhan V, Sahay RR, Shete AM, Yadav PD, Sahoo B, Patil DY, Kumar S, Premachandran Syamaladevi KS, Dar L, Mohandas S, and Abraham P
- Subjects
- Male, Humans, Female, Monkeypox virus genetics, India, Mpox (monkeypox) diagnosis, Mpox (monkeypox) epidemiology, Sex Workers, Sexually Transmitted Diseases
- Abstract
We describe the clinical and demographic characteristics, virological follow-up, and management of five confirmed monkeypox cases from New Delhi, India without any international travel history. The viral load kinetics and viral clearance were estimated in oropharyngeal swabs (OPS), nasopharyngeal swabs (NPS), EDTA blood, serum, urine, and various lesion specimens on every fourth day of follow-up ranging from 5 to 24 post onset day (POD) of illness. All five cases presented with mild to moderate-grade intermittent fever, myalgia, and lesions on the genitals, groins, lower limb, trunk, and upper limb. Four cases had non-tender firm lymphadenopathy. No secondary complications or sexually transmitted infections were recorded in these cases except for the presence of viral hepatitis B infection marker hepatitis B virus surface antigen (HBsAg) in one case. All the cases were mild and had a good recovery. A higher viral load was detected in lesion fluid (POD 9), followed by lesion roof (POD 9), urine (POD 5), lesion base (POD 5), and OPS/NPS (POD 5). The monkeypox virus (MPXV) DNA was detected in clinical samples from 5th to 24th POD. These monkeypox cases without international travel history suggest the underdiagnosed monkeypox infection in the community. This emphasizes the need for active surveillance of MPXV in the high-risk population such as men having sex with men and female sex workers., (© 2022 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
34. Cases of SARS-CoV-2 reinfection with Omicron BA.2 post breakthrough infection with Delta and Kappa variants.
- Author
-
Sahay RR, Patil DY, Sapkal GN, Shete AM, and Yadav PD
- Subjects
- Humans, Breakthrough Infections, SARS-CoV-2, COVID-19
- Published
- 2023
- Full Text
- View/download PDF
35. Genome characterization of monkeypox cases detected in India: Identification of three sub clusters among A.2 lineage.
- Author
-
Shete AM, Yadav PD, Kumar A, Patil S, Patil DY, Joshi Y, Majumdar T, Relhan V, Sahay RR, Vasu M, Gawande P, Verma A, Kumar A, Dhakad S, Krishnan AB, Chenayil S, Kumar S, and Abraham P
- Subjects
- Humans, Phylogeny, Genome, Viral, India epidemiology, Mpox (monkeypox)
- Abstract
Competing Interests: Declaration of Competing Interest Authors do not have a conflict of interest among themselves.
- Published
- 2023
- Full Text
- View/download PDF
36. Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months.
- Author
-
Sahay RR, Yadav PD, Nandapurkar A, Dhawde R, Suryawanshi A, Patil DY, Shete AM, Sapkal GN, Kulkarni M, Gurav YK, Deshpande GR, Ghodke JS, Jain R, Hawale R, Kalele K, Yemul J, Gawande P, and Abraham P
- Subjects
- Adult, Humans, SARS-CoV-2, Antibodies, Neutralizing, Antibodies, Viral, Immunogenicity, Vaccine, COVID-19 Vaccines, COVID-19 prevention & control
- Abstract
We have evaluated the immunogenicity of two dose of Covaxin given at a one-month interval to two adult populations, i.e. COVID-19 naïve-vaccinated individuals (n = 118) and COVID-19 recovered individuals (n = 128) with the vaccination. The immune response in the study population were assessed at three follow-ups, namely at one month post first dose, one and six months after the second dose. The persistence of S1RBD IgG and neutralizing antibodies for six months post vaccination was observed at different time intervals. The enhanced immune response was observed in both the participant groups. The study emphasizes the need for a booster dose post six months of vaccination.
- Published
- 2022
- Full Text
- View/download PDF
37. Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report.
- Author
-
Cable J, Fauci A, Dowling WE, Günther S, Bente DA, Yadav PD, Madoff LC, Wang LF, Arora RK, Van Kerkhove M, Chu MC, Jaenisch T, Epstein JH, Frost SDW, Bausch DG, Hensley LE, Bergeron É, Sitaras I, Gunn MD, Geisbert TW, Muñoz-Fontela C, Krammer F, de Wit E, Nordenfelt P, Saphire EO, Gilbert SC, Corbett KS, Branco LM, Baize S, van Doremalen N, Krieger MA, Clemens SAC, Hesselink R, and Hartman D
- Subjects
- Humans, Pandemics, Disease Outbreaks, COVID-19 epidemiology, Ebolavirus
- Abstract
The COVID-19 pandemic caught the world largely unprepared, including scientific and policy communities. On April 10-13, 2022, researchers across academia, industry, government, and nonprofit organizations met at the Keystone symposium "Lessons from the Pandemic: Responding to Emerging Zoonotic Viral Diseases" to discuss the successes and challenges of the COVID-19 pandemic and what lessons can be applied moving forward. Speakers focused on experiences not only from the COVID-19 pandemic but also from outbreaks of other pathogens, including the Ebola virus, Lassa virus, and Nipah virus. A general consensus was that investments made during the COVID-19 pandemic in infrastructure, collaborations, laboratory and manufacturing capacity, diagnostics, clinical trial networks, and regulatory enhancements-notably, in low-to-middle income countries-must be maintained and strengthened to enable quick, concerted responses to future threats, especially to zoonotic pathogens., (© 2022 New York Academy of Sciences.)
- Published
- 2022
- Full Text
- View/download PDF
38. Delta variant SARS-CoV-2 infections in pediatric cases during the second wave in India.
- Author
-
Yadav PD, Kumar G, Mukherjee A, Nyayanit DA, Shete AM, Sahay RR, Kumar A, Majumdar T, Patil S, Pandit P, Joshi Y, Dudhmal M, Panda S, Sharma LK, Yadav Ml K, Shastri J, Gangwar M, Munivenkattapa A, Potdar V, Nagamani K, Goyal K, Gadepalli R, Thomas M, Shukla S, Nagraj P, Gupta V, Dalela G, Umar N, and Patel SM
- Subjects
- Humans, Child, SARS-CoV-2 genetics, India epidemiology, Asian People, COVID-19 epidemiology
- Abstract
Background: During October 2020, Delta variant was detected for the first time in India and rampantly spread across the globe. It also led to second wave of pandemic in India which affected millions of people. However, there is limited information pertaining to the SARS-CoV-2 strain infecting the children in India., Methods: Here, we assessed the SARS-CoV-2 lineages circulating in the pediatric population of India during the second wave of the pandemic. Clinical and demographic details linked with the nasopharyngeal/oropharyngeal swabs (NPS/OPS) collected from SARS-CoV-2 cases (n = 583) aged 0-18 year and tested positive by real-time RT-PCR were retrieved from March to June 2021., Results: Symptoms were reported among 37.2% of patients and 14.8% reported to be hospitalized. The E gene CT value had significant statistical difference at the point of sample collection when compared to that observed in the sequencing laboratory. Out of these 512 sequences 372 were VOCs, 51 were VOIs. Most common lineages observed were Delta, followed by Kappa, Alpha and B.1.36, seen in 65.82%, 9.96%, 6.83% and 4.68%, respectively in the study population., Conclusion: Overall, it was observed that Delta strain was the leading cause of SARS-CoV-2 infection in Indian children during the second wave of the pandemic. We emphasize on the need of continuous genomic surveillance in SARS-CoV-2 infection even amongst children., Competing Interests: Declaration of competing interest The authors declare no conflict of interest., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
39. Community transmission of SARS-CoV-2 with B.1.1.7 lineage in Mumbai, India.
- Author
-
Shastri J, Yadav PD, Agrawal S, Shete AM, Nyayanit DA, Parikh S, Gomare M, Sahay RR, Patil DY, Dudhmal M, and Kadam N
- Subjects
- Humans, India epidemiology, SARS-CoV-2, COVID-19 epidemiology
- Abstract
The B.1.1.7 (Alpha) variant has been detected in Mumbai, India during February 2021. Subsequently, we retrieved 43 sequences from specimens of 51 COVID-19 cases from Mumbai. The sequence analysis revealed that the cases were mainly affected with Alpha variant which suggests its role in community transmission of SARS-CoV-2 in Mumbai, India., Competing Interests: Declaration of competing interest No conflict of interest exists among authors., (Copyright © 2021. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
40. Waning natural and vaccine-induced immunity leading to reinfection with SARS-CoV-2 Omicron variant.
- Author
-
Shete AM, Patil DY, Sahay RR, Sapkal GN, Deshpande GR, and Yadav PD
- Subjects
- Humans, SARS-CoV-2 genetics, ChAdOx1 nCoV-19, Reinfection prevention & control, COVID-19 prevention & control, Vaccines
- Abstract
We have investigated six COVID-19 recovered cases with two doses of Covishield vaccination followed by reinfection. The primary SARS-CoV-2 infection found to occur with B.1 and reinfection with Omicron BA.1 and BA.2 variants. The genomic characterization and duration between two infections confirms these cases as SARS-CoV-2 reinfection. The immune response determined at different time intervals demonstrated boost post two dose vaccination, decline in pre-reinfection sera post 7 months and rise post reinfection. In conclusion, it was observed that these cases got SARS-CoV-2 reinfection with declined hybrid immunity acquired from primary infection and two dose covishield vaccination. This findings suggests the need to protect the community through booster dose of vaccination and prevent further infections following personal hygiene and non-pharmaceutical interventions.
- Published
- 2022
- Full Text
- View/download PDF
41. Differential Cell Line Susceptibility to the SARS-CoV-2 Omicron BA.1.1 Variant of Concern.
- Author
-
Dighe H, Sarkale P, Patil DY, Mohandas S, Shete AM, Sahay RR, Lakra R, Patil S, Majumdar T, Gawande P, Yemul J, Vedpathak P, and Yadav PD
- Abstract
The unique mutations of the SARS-CoV-2 Omicron variant are associated with increased transmissibility, immune escape, increased binding affinity to ACE-2, and increased viral load. Omicron exhibited a shift in tropism infecting the upper respiratory tract compared to other variants of concern which have tropism for the lower respiratory tract. The tropism of omicron variants in cell lines of different hosts and tissue origins still remains unclear. Considering this, we assessed the susceptibility of different cell lines to the SARS-CoV-2 omicron BA.1.1 variant and permissiveness among different cell lines for omicron replication. Susceptibility and permissiveness of a total of eleven cell lines, including six animal cell lines and five human cell lines for omicron BA.1.1 infection, were evaluated by infecting individual cell lines with omicron BA.1.1 isolate at a 0.1 multiplicity of infection. Virus replication was assessed by observation of cytopathic effects followed by viral load determination by real-time PCR assay and virus infectivity determination by TCID50 assay. The characteristic cytopathic effect, increased viral load, and productive omicron replication was detected in Vero CCL-81, Vero E6, Vero/hSLAM, MA-104, and Calu-3 cells. Although LLC MK-2 cells showed an increased TCID50 titer at the second infection, the viral load did not show much difference in both infections. Caco-2 cells did not show evident CPE, but they supported omicron replication at a low level. A549, RD, MRC-5, and BHK-21 cells supported omicron BA.1.1 replication without the CPE. This is the first study on the comparison of susceptibility of different cell lines to Omicron variant BA.1.1, which might be useful for future studies on emerging SARS-CoV-2 variants.
- Published
- 2022
- Full Text
- View/download PDF
42. A case control investigation of COVID-19 associated mucormycosis in India.
- Author
-
Anand T, Mukherjee A, Satija A, Velamuri PS, Singh KJ, Das M, Josten K, Yadav PD, Sahay RR, Keche AY, Nagarkar NM, Gupta P, Himanshu D, Mistry SN, Patel JD, Rao P, Rohatgi S, Ghosh S, Hazra A, Kindo AJ, Annamalai R, Rudramurthy SM, Singh MP, Shameem M, Fatima N, Khambholja JR, Parikh S, Madkaikar M, Pradhan VD, Kataria S, Sharma P, and Panda S
- Subjects
- Humans, Pandemics, SARS-CoV-2, India epidemiology, Case-Control Studies, COVID-19 epidemiology
- Abstract
Background: Increased occurrence of mucormycosis during the second wave of COVID-19 pandemic in early 2021 in India prompted us to undertake a multi-site case-control investigation. The objectives were to examine the monthly trend of COVID-19 Associated Mucormycosis (CAM) cases among in-patients and to identify factors associated with development of CAM., Methods: Eleven study sites were involved across India; archived records since 1st January 2021 till 30th September 2021 were used for trend analysis. The cases and controls were enrolled during 15th June 2021 to 30th September 2021. Data were collected using a semi-structured questionnaire. Among 1211 enrolled participants, 336 were CAM cases and 875 were COVID-19 positive non-mucormycosis controls., Results: CAM-case admissions reached their peak in May 2021 like a satellite epidemic after a month of in-patient admission peak recorded due to COVID-19. The odds of developing CAM increased with the history of working in a dusty environment (adjusted odds ratio; aOR 3.24, 95% CI 1.34, 7.82), diabetes mellitus (aOR: 31.83, 95% CI 13.96, 72.63), longer duration of hospital stay (aOR: 1.06, 95% CI 1.02, 1.11) and use of methylprednisolone (aOR: 2.71, 95% CI 1.37, 5.37) following adjustment for age, gender, occupation, education, type of houses used for living, requirement of ventilatory support and route of steroid administration. Higher proportion of CAM cases required supplemental oxygen compared to the controls; use of non-rebreather mask (NRBM) was associated as a protective factor against mucormycosis compared to face masks (aOR: 0.18, 95% CI 0.08, 0.41). Genomic sequencing of archived respiratory samples revealed similar occurrences of Delta and Delta derivates of SARS-CoV-2 infection in both cases and controls., Conclusions: Appropriate management of hyperglycemia, judicious use of steroids and use of NRBM during oxygen supplementation among COVID-19 patients have the potential to reduce the risk of occurrence of mucormycosis. Avoiding exposure to dusty environment would add to such prevention efforts., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
43. Omicron BA.2 lineage predominance in severe acute respiratory syndrome coronavirus 2 positive cases during the third wave in North India.
- Author
-
Zaman K, Shete AM, Mishra SK, Kumar A, Reddy MM, Sahay RR, Yadav S, Majumdar T, Pandey AK, Dwivedi GR, Deval H, Singh R, Behera SP, Kumar N, Patil S, Kumar A, Dudhmal M, Joshi Y, Shukla A, Gawande P, Kavathekar A, Kumar N, Kumar V, Kumar K, Singh RS, Kumar M, Tiwari S, Verma A, Yadav PD, and Kant R
- Abstract
Background: Recent studies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reveal that Omicron variant BA.1 and sub-lineages have revived the concern over resistance to antiviral drugs and vaccine-induced immunity. The present study aims to analyze the clinical profile and genome characterization of the SARS-CoV-2 variant in eastern Uttar Pradesh (UP), North India., Methods: Whole-genome sequencing (WGS) was conducted for 146 SARS-CoV-2 samples obtained from individuals who tested coronavirus disease 2019 (COVID-19) positive between the period of 1 January 2022 and 24 February 2022, from three districts of eastern UP. The details regarding clinical and hospitalized status were captured through telephonic interviews after obtaining verbal informed consent. A maximum-likelihood phylogenetic tree was created for evolutionary analysis using MEGA7., Results: The mean age of study participants was 33.9 ± 13.1 years, with 73.5% accounting for male patients. Of the 98 cases contacted by telephone, 30 (30.6%) had a travel history (domestic/international), 16 (16.3%) reported having been infected with COVID-19 in past, 79 (80.6%) had symptoms, and seven had at least one comorbidity. Most of the sequences belonged to the Omicron variant, with BA.1 (6.2%), BA.1.1 (2.7%), BA.1.1.1 (0.7%), BA.1.1.7 (5.5%), BA.1.17.2 (0.7%), BA.1.18 (0.7%), BA.2 (30.8%), BA.2.10 (50.7%), BA.2.12 (0.7%), and B.1.617.2 (1.3%) lineages. BA.1 and BA.1.1 strains possess signature spike mutations S:A67V, S:T95I, S:R346K, S:S371L, S:G446S, S:G496S, S:T547K, S:N856K, and S:L981F, and BA.2 contains S:V213G, S:T376A, and S:D405N. Notably, ins214EPE (S1- N-Terminal domain) mutation was found in a significant number of Omicron BA.1 and sub-lineages. The overall Omicron BA.2 lineage was observed in 79.5% of women and 83.2% of men., Conclusion: The current study showed a predominance of the Omicron BA.2 variant outcompeting the BA.1 over a period in eastern UP. Most of the cases had a breakthrough infection following the recommended two doses of vaccine with four in five cases being symptomatic. There is a need to further explore the immune evasion properties of the Omicron variant., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Zaman, Shete, Mishra, Kumar, Reddy, Sahay, Yadav, Majumdar, Pandey, Dwivedi, Deval, Singh, Behera, Kumar, Patil, Kumar, Dudhmal, Joshi, Shukla, Gawande, Kavathekar, Kumar, Kumar, Kumar, Singh, Kumar, Tiwari, Verma, Yadav and Kant.)
- Published
- 2022
- Full Text
- View/download PDF
44. First two cases of Monkeypox virus infection in travellers returned from UAE to India, July 2022.
- Author
-
Yadav PD, Reghukumar A, Sahay RR, K S, Shete AM, Raman A, Vk P, Abraham P, Benson R, Sm S, Mohandas S, Patil DY, Kumar A, Gupta N, George AE, Vijay N, U A, Suresh M, A RR, Sapkal GN, Ravindranath M, Sreenivasan S, James P, and Mk S
- Subjects
- Humans, India epidemiology, Mpox (monkeypox) diagnosis, Mpox (monkeypox) epidemiology, Monkeypox virus
- Abstract
Competing Interests: Conflicts of Interest Authors do not have a conflict of interest among themselves.
- Published
- 2022
- Full Text
- View/download PDF
45. Protective efficacy of COVAXIN® against Delta and Omicron variants in hamster model.
- Author
-
Yadav PD, Mohandas S, Shete A, Sapkal G, Deshpande G, Kumar A, Wakchaure K, Dighe H, Jain R, Ganneru B, Yemul J, Gawande P, Vadrevu KM, and Abraham P
- Abstract
The immunity acquired after natural infection or vaccinations against SARS-CoV-2 tend to wane with time. Here, we compared the protective efficacy of COVAXIN® following two- and three-dose immunizations against the Delta variant and also studied the efficacy of COVAXIN® against Omicron variants in a Syrian hamster model. Despite the comparable neutralizing antibody response against the homologous vaccine strain in both the two-dose and three-dose immunized groups, considerable reduction in the lung disease severity was observed in the 3 dose immunized group after Delta variant challenge. In the challenge study using the Omicron variants, i.e., BA.1.1 and BA.2, lesser virus shedding, lung viral load and lung disease severity were observed in the immunized groups. The present study shows that administration of COVAXIN® booster dose will enhance the vaccine effectiveness against the Delta variant infection and give protection against the BA.1.1 and BA.2 variants., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
46. Lack of evidence of viability and infectivity of SARS-CoV-2 in the fecal specimens of COVID-19 patients.
- Author
-
Joshi M, Mohandas S, Prasad S, Shinde M, Chavan N, Yadav PD, and Lavania M
- Subjects
- Humans, Sewage, RNA, Viral, Feces, SARS-CoV-2, COVID-19
- Abstract
SARS-CoV-2 can be shed in feces and can enter sewage systems. In order to implement effective control measures and identify new channels of transmission, it is essential to identify the presence of infectious virus particles in feces and sewage. In this study, we attempt to utilize Molecular techniques, cell cultures and animal models to find out the infectivity of SARS-CoV-2 in the feces of COVID-19 patients. Our findings exclude the presence of infectious virus particles, suggesting that fecal-oral transmission may not be the main mode of transmission. Larger-scale initiatives are nevertheless required, particularly considering the emergence of new viral strains., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Joshi, Mohandas, Prasad, Shinde, Chavan, Yadav and Lavania.)
- Published
- 2022
- Full Text
- View/download PDF
47. First case of Zika virus infection during an outbreak of chikungunya in a rural region of Maharashtra state, India.
- Author
-
Gurav YK, Alagarasu K, Yadav PD, Sapkal G, Gokhale M, Parashar D, Jadhav U, Bote M, Kakade M, Nyayanit D, Kumar A, Deshpande GR, Cherian S, Awate PS, and Abraham P
- Subjects
- Disease Outbreaks, Humans, India epidemiology, Chikungunya Fever epidemiology, Chikungunya virus genetics, Dengue epidemiology, Dengue Virus genetics, Zika Virus genetics, Zika Virus Infection diagnosis, Zika Virus Infection epidemiology
- Abstract
Background: In July 2021, an outbreak of chikungunya virus (CHIKV) was reported in a rural region of Maharashtra state, India., Methods: Serum samples of symptomatic cases (n=33) were screened for dengue virus (DENV), CHIKV and Zika virus (ZIKV) by molecular and serological assays., Results: The first case of ZIKV infection from Maharashtra was detected and confirmed by molecular and serological assays. Complete genome sequencing revealed that the ZIKV sequence belongs to the Asian genotype and had a closer homology with pre-epidemic strains present before 2007., Conclusions: ZIKV surveillance needs to be strengthened in the regions experiencing dengue and chikungunya outbreaks., (© The Author(s) 2022. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.)
- Published
- 2022
- Full Text
- View/download PDF
48. Genomic profile of SARS-CoV-2 Omicron variant and its correlation with disease severity in Rajasthan.
- Author
-
Sharma RP, Gautam S, Sharma P, Singh R, Sharma H, Parsoya D, Deeba F, Bhomia N, Pal N, Potdar V, Yadav PD, Gupta N, Bhandari S, Kumar A, Joshi Y, Pandit P, and Malhotra B
- Abstract
Background: Omicron, a new variant of Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2), was first detected in November 2021. This was believed to be highly transmissible and was reported to evade immunity. As a result, an urgent need was felt to screen all positive samples so as to rapidly identify Omicron cases and isolate them to prevent the spread of infection. Genomic surveillance of SARS-CoV-2 was planned to correlate disease severity with the genomic profile., Methods: All the SARS-CoV-2 positive cases detected in the state of Rajasthan were sent to our Lab. Samples received from 24 November 2021 to 4 January 2022 were selected for Next-Generation Sequencing (NGS). Processing was done as per protocol on the Ion Torrent S5 System for 1,210 samples and bioinformatics analysis was done., Results: Among the 1,210 samples tested, 762 (62.9%) were Delta/Delta-like and other lineages, 291 (24%) were Omicron, and 157 (12.9%) were invalid or repeat samples. Within a month, the proportion of Delta and other variants was reversed, 6% Omicron became 81%, and Delta and other variants became 19%, initially all Omicron cases were seen in international travelers and their contacts but soon community transmission was seen. The majority of patients with Omicron were asymptomatic (56.7%) or had mild disease (33%), 9.2% had moderate symptoms, and two (0.7%) had severe disease requiring hospitalization, of which one (0.3%) died and the rest were (99.7%) recovered. History of vaccination was seen in 81.1%, of the previous infection in 43.2% of cases. Among the Omicron cases, BA.1 (62.8%) was the predominant lineage followed by BA.2 (23.7%) and B.1.529 (13.4%), rising trends were seen initially for BA.1 and later for BA.2 also. Although 8.9% of patients with Delta lineage during that period were hospitalized, 7.2% required oxygen, and 0.9% died. To conclude, the community spread of Omicron occurred in a short time and became the predominant circulating variant; BA.1 was the predominant lineage detected. Most of the cases with Omicron were asymptomatic or had mild disease, and the mortality rate was very low as compared to Delta and other lineages., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Sharma, Gautam, Sharma, Singh, Sharma, Parsoya, Deeba, Bhomia, Pal, Potdar, Yadav, Gupta, Bhandari, Kumar, Joshi, Pandit and Malhotra.)
- Published
- 2022
- Full Text
- View/download PDF
49. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
- Author
-
Bhatnagar T, Chaudhuri S, Ponnaiah M, Yadav PD, Sabarinathan R, Sahay RR, Ahmed F, Aswathy S, Bhardwaj P, Bilimale A, Kumar MS, Logaraj M, Narlawar U, Palanivel C, Patel P, Rai SK, Saxena V, Singh A, Thangaraj JW, Agarwal A, Alvi Y, Amoghashree, Ashok P, Babu D, Bahurupi Y, Bhalavi S, Behera P, Biswas PP, Charan J, Chauhan NK, Chetak KB, Dar L, Das A, Deepashree R, Dhar M, Dhodapkar R, Dipu TS, Dudeja M, Dudhmal M, Gadepalli R, Garg MK, Gayathri AV, Goel AD, Gowdappa HB, Guleria R, Gupta MK, Islam F, Jain M, Jain V, Jawahar MLS, Joshi R, Kant S, Kar SS, Kalita D, Khapre M, Khichar S, Kombade SP, Kohli S, Kumar A, Kumar A, Kumar D, Kulirankal KG, Leela KV, Majumdar T, Mishra B, Misra P, Misra S, Mohapatra PR, Murthy MN, Nyayanit DA, Patel M, Pathania M, Patil S, Patro BK, Jalandra R, Rathod P, Shah N, Shete A, Shukla D, Shwethashree M, Sinha S, Sumana MN, Surana A, Trikha A, Tejashree A, Venkateshan M, Vijaykrishnan G, Wadhava S, Wig N, Gupta N, Abraham P, and Murhekar MV
- Subjects
- COVID-19 Vaccines, Case-Control Studies, ChAdOx1 nCoV-19, Hospitals, Humans, SARS-CoV-2, COVID-19 epidemiology, COVID-19 prevention & control, Influenza Vaccines
- Abstract
Objectives: India introduced BBV152/Covaxin and AZD1222/Covishield vaccines in January 2021. We estimated the effectiveness of these vaccines against severe COVID-19 among individuals aged ≥45 years., Methods: We did a multi-centric, hospital-based, case-control study between May and July 2021. Cases were severe COVID-19 patients, and controls were COVID-19 negative individuals from 11 hospitals. Vaccine effectiveness (VE) was estimated for complete (2 doses ≥ 14 days) and partial (1 dose ≥ 21 days) vaccination; interval between two vaccine doses and vaccination against the Delta variant. We used the random effects logistic regression model to calculate the adjusted odds ratios (aOR) with a 95% confidence interval (CI) after adjusting for relevant known confounders., Results: We enrolled 1143 cases and 2541 control patients. The VE of complete vaccination was 85% (95% CI: 79-89%) with AZD1222/Covishield and 71% (95% CI: 57-81%) with BBV152/Covaxin. The VE was highest for 6-8 weeks between two doses of AZD1222/Covishield (94%, 95% CI: 86-97%) and BBV152/Covaxin (93%, 95% CI: 34-99%). The VE estimates were similar against the Delta strain and sub-lineages., Conclusion: BBV152/Covaxin and AZD1222/Covishield were effective against severe COVID-19 among the Indian population during the period of dominance of the highly transmissible Delta variant in the second wave of the pandemic. An escalation of two-dose coverage with COVID-19 vaccines is critical to reduce severe COVID-19 and further mitigate the pandemic in the country., (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
50. Development of Nipah virus-specific IgM & IgG ELISA for screening human serum samples.
- Author
-
Shete AM, Jain R, Mohandas S, Pardeshi P, Yadav PD, Gupta N, and Mourya D
- Subjects
- Humans, Antibodies, Viral, Immunoglobulin M, Enzyme-Linked Immunosorbent Assay, Immunoglobulin G, Sensitivity and Specificity, Nipah Virus
- Abstract
Background & Objectives: Nipah virus (NiV) is a zoonotic paramyxovirus that causes fatal encephalitis in humans. Enzyme Linked Immunosorbent Assay (ELISA) is a safe, sensitive, specific, and affordable diagnostic tool that can be used during screening of large-scale epidemiological investigations. Development and evaluation of IgM and IgG ELISA for screening serum samples of NiV suspected cases would also help in planning public health interventions., Methods: An IgM capture (MAC) ELISA and an indirect IgG ELISA were developed using NiV antigen to detect IgM and IgG antibodies against NiV in human sera. The sensitivity, specificity, and cross-reactivity of the assays were evaluated using NiV IgM, IgG positive, negative human sera and measles, mumps, rubella, Crimean-Congo haemorrhagic fever, Kyasanur forest disease IgM, IgG positive sera, respectively., Results: The developed anti-NiV IgM and IgG ELISAs have shown specificity of 99.28 per cent and sensitivity of 100 per cent compared to reference test from Centers for Disease Control and Prevention, USA. Assays demonstrated negative predictive value of 100 per cent and positive predictive value as 90 and 93.94 per cent for anti-Nipah IgM ELISA and IgG ELISA respectively with test accuracy of 99.33 per cent., Interpretation & Conclusions: Timely diagnosis of NiV is crucial for the management of cases, which could prevent further spread of infection in the community. IgM ELISA can be used as primary diagnostic tool followed by polymerase chain reaction. These assays have advantages of its applicability during outbreak investigations and surveillance activities at hospital or onsite laboratories with basic biosafety practices.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.